Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06868290 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
A Phase 2 study of ANCA-Associated Vasculitis (AAV), sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 126
- Enrollment target
- 20
- Study locations
NCT06868290: Recruiting Phase 2 study of ANCA-Associated Vasculitis (AAV), sponsored by Novartis Pharmaceuticals.
NCT06868290 is a Phase 2 study of ANCA-Associated Vasculitis (AAV) that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 126 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06868290, a Phase 2 study of ANCA-Associated Vasculitis (AAV), is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 126 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe active Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)
Primary Outcome
Event-free survival (EFS) defined as the time from Randomization to the first occurrence of as per protocol defined events.
Conditions Studied
Interventions
- OTHER Active Comparator
- BIOLOGICAL Rapcabtagene autoleucel
- DRUG Glucocorticoids
Study Locations (20)
Other
- Novartis Investigative Site - São Paulo
- Novartis Investigative Site - Haifa
- Novartis Investigative Site - Ramat Gan
São Paulo
- Novartis Investigative Site - Barretos
- Novartis Investigative Site - São Paulo
Colorado
- University Of Colorado - Aurora
Florida
- Mayo Clinic Jacksonville - Jacksonville
Illinois
- Northwestern University - Chicago
Massachusetts
- Massachusetts General Hospital - Boston
Minnesota
- Mayo Clinic Rochester - Rochester
Oregon
- Oregon Health Sciences University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2025-03-13 |
| Est. Completion | 2030-05-24 |
| Phase | Phase 2 |
What NCT06868290 shows while recruiting
NCT06868290 is an interventional study that assigns participants to a tested intervention. The registered 126 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 1 condition, with ANCA-Associated Vasculitis (AAV) appearing as the primary indexed condition, and to 3 interventions - of which Active Comparator is the first listed.
NCT06868290 names 20 study sites across 17 states, led by Other, São Paulo, Colorado.
Frequently Asked Questions
What is clinical trial NCT06868290 about?
NCT06868290 is a clinical study titled "Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA". The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe active Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)
What is the current status of trial NCT06868290?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 126 participants. The study started on 2025-03-13. Estimated completion is 2030-05-24.
What conditions does trial NCT06868290 study?
This clinical trial studies the following conditions: ANCA-Associated Vasculitis (AAV).
What interventions are being tested in trial NCT06868290?
The interventions under investigation include: Active Comparator (OTHER), Rapcabtagene autoleucel (BIOLOGICAL), Glucocorticoids (DRUG).
Who is sponsoring clinical trial NCT06868290?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06868290 being conducted?
This trial has 20 study locations across Colorado, Florida, Illinois, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ANCA-Associated Vasculitis (AAV)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06868290's enrollment target sits among peer trials
126 556th of 2000 higher than 1,443 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01873131 · 126 participants · NA
A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn
- NCT02621645 · 126 participants · Phase 4
TRAP Intervention STudy: Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence
- NCT03838107 · 126 participants
Markers of Trajectory in Pediatric CRPS
- NCT03906422 · 126 participants · NA
Comparison of Patient-reported Pain After Initial Archwire Placement
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI